Inotiv Inc Stock Price, News & Analysis

Inotiv, Inc. (NASDAQ: NOTV) announced it will release its financial results for Q2 FY2022 on May 12, 2022, after market close. A conference call will follow at 4:30 p.m. ET the same day to discuss the results. Interested participants can join via specified domestic and international phone numbers. The call will also be webcasted and accessible through the company's investors' section. The company focuses on providing nonclinical and analytical drug discovery services.

On April 25, 2022, Inotiv, Inc. (NASDAQ: NOTV) announced the acquisition of Histion, LLC, as part of its strategy to expand specialized pathology services. This acquisition enhances Inotiv's histology operations in the plastics and medical device sectors, supporting its previously announced expansion of surgical models and medical device testing services in Fort Collins, CO. Chief Operating Officer Greg Beattie emphasized the benefits of Histion's expertise in improving client support, while Histion's President Peggy Lalor expressed enthusiasm about integrating their pathology services with Inotiv's offerings.

Inotiv, Inc. (NASDAQ: NOTV) reported a significant 370.4% revenue increase for Q1 FY 2022, totaling $84.2 million, compared to $17.9 million in Q1 FY 2021. This growth was driven by acquisitions and internal growth. However, the company recorded a net loss of $83.0 million, or $(3.93) per share, reflecting increased operating expenses, including $23.0 million in stock compensation due to acquisitions. Adjusted EBITDA rose to $10.1 million, up 621.4%. DSA backlog increased 130.9% to $104.6 million, indicating robust future revenue prospects.

Inotiv, Inc. (NASDAQ: NOTV) will release its financial results for the fiscal 2022 first quarter, ending December 31, 2021, on February 10, 2022, after market close. The Company will host a conference call at 4:30 p.m. ET on the same day for discussion of the results. Interested participants can join via domestic and international dialing options. The live webcast will be accessible on the Investors section of Inotiv's website, with a replay available post-broadcast. Inotiv specializes in drug discovery and development services, focusing on improving efficiency and reducing costs in bringing new drugs to market.

Inotiv (NASDAQ: NOTV) has acquired Orient BioResource Center (OBRC) for $51.3 million, including $28.3 million in cash and approximately 677,339 shares valued at $23.0 million. The acquisition aims to enhance Inotiv's capabilities by integrating OBRC's primate facility in Alice, Texas, which spans 500 acres and generated $23 million in revenue in fiscal 2021. This strategic move seeks to fulfill client demands for increased research model access while maintaining high animal welfare standards.

Inotiv, Inc. (NASDAQ: NOTV) announced the acquisition of Integrated Laboratory Systems, LLC (ILS) for $56 million, comprising $38 million in cash and 429,118 shares valued at $18 million. ILS, specializing in genetic toxicology and related services, reported $20 million in revenue for 2021. This acquisition enhances Inotiv's capacity in toxicology services and extends its expertise into genomics and bioinformatics. The addition of ILS is anticipated to broaden Inotiv's market reach and create significant cross-selling opportunities, retaining all existing ILS employees.

Inotiv, Inc. (NASDAQ: NOTV) has announced the acquisition of the rabbit breeding and supply business from Robinson Services Inc. (RSI). This move aims to enhance Inotiv's Research Models and Services (RMS) sector by consolidating RSI's assets, including its customer list and a supply agreement for rabbits. The acquisition is expected to optimize Inotiv’s global footprint and offer a wider range of options for clients. Inotiv plans to integrate RSI's operations into its existing facilities throughout 2022, positioning itself for future growth in the research and drug development markets.

Inotiv, Inc. (NASDAQ: NOTV) and Synexa Life Sciences announced a strategic collaboration aimed at enhancing the development of biotherapeutics through advanced biomarker analysis. This partnership is expected to broaden Inotiv's service offerings, enhance customer reach, and create cost and revenue synergies. Synexa will establish U.S. operations at Inotiv's Rockville, MD facility, supporting the development of GLP-compliant biomarker services. The collaboration aims to simplify outsourcing for biopharmaceutical companies and foster preferred provider partnerships in an increasingly complex drug development landscape.

Inotiv, Inc. (NASDAQ: NOTV) reported significant growth in Q4 and FY 2021. Q4 revenue surged by 90.7% to $30.1 million, driven by acquisitions and internal growth, while FY 2021 revenue increased 48.2% to $89.6 million. Net income for Q4 reached $9.4 million compared to a net loss of $(1.8) million in Q4 2020, aided by PPP loan forgiveness. Operating expenses rose 128.8% in Q4 due to strategic investments. The company reported a backlog of $81.4 million by quarter-end, indicating strong future revenue potential.